Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-04-20
1996-05-21
Jordan, Kimberly
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514885, A61K 3140
Patent
active
055190472
ABSTRACT:
A method of decreasing elevated levels of IL-6 and .gamma.-IFN that are secreted in response to traumatic injury in a warm-blooded animal is disclosed, comprising the step of administering an effective amount of melatonin to the animal. The melatonin should be administered so as to provide a peak amount of circulating melatonin at a time in the animal's daily cycle when endogenous melatonin reaches peak amounts. Elevated levels of IL-6 and .gamma.-IFN are also decreased by exposing the animal to certain daily regimens of light and dark, such as 24 hours of dark. Cell-mediated immune response to a contact antigen is also enhanced by administration of exogenous melatonin.
REFERENCES:
patent: 4855325 (1989-08-01), Naftchi
CA 115:106637, Fraschini et al., 1990.
CA 116: 249055, Caroleo et al., 1992.
CA 117: 46488, Wang et al., 1992.
CA 108: 143860, Maestroni et al., 1988.
CA 121: 253426, Muscettola et al., 1994.
Nielson Harold C.
Shelby Jane
Jordan Kimberly
University of Utah Research Foundation
LandOfFree
Immunomodulatory activity of exogenous melatonin following traum does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunomodulatory activity of exogenous melatonin following traum, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunomodulatory activity of exogenous melatonin following traum will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2038380